TapImmune Announces Progress in Phase II Trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

TapImmune Inc. said Memorial Sloan Kettering Cancer Center successfully completed the first safety cohort in its phase II ovarian cancer study.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval a Type II variation for Rubraca (rucaparib), as a first-line maintenance treatment for all women with advanced ovarian cancer regardless of their BRCA mutation status, who have responded to first-line platinum-based chemotherapy. 
Findings from two subset analyses of the phase III MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of Elahere (mirvetuximab soravtansine-gynx) compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer demonstrate an overall survival and progression-free survival benefit. 

Login